FTC’s China-linked remedy-buyer stance could test line between antitrust, CFIUS
By Flavia Fortes ( September 24, 2026, 18:42 GMT | Comment) -- US Federal Trade Commission Chair Andrew Ferguson’s warning that he may reject a divestiture to a Chinese Communist Party-controlled buyer puts a new practical constraint on merger remedies: a buyer that appears capable of preserving competition may not be acceptable to the antitrust agency.US Federal Trade Commission Chair Andrew Ferguson’s warning that he may reject a divestiture to a Chinese Communist Party-controlled buyer puts a new practical constraint on merger remedies: a buyer that appears capable of preserving competition may not be acceptable to the antitrust agency....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.